realized that tumors arise largely, if not exclusively, by sequential changes at the DNA level. This vast field can now be approached in concrete molecular terms. The identification of both tumor-driving and tumor-antagonizing genes is a testimony to the rapid progress that has taken place and also to the foresight of the organizers. It may be added that Japanese groups are in the forefront of the most important recent work in the field of tumor suppressor genes.
The list of the other Princess Takamatsu Symposia leaves no doubt that they have been equally focused on important problems of carcinogenesis and probably had a comparably great impact on their respective fields.
All foreign participants I know have agreed that the symposia have been of the highest quality and were conducted in an atmosphere of scientific curiosity, precision, excitement and informal friendly exchanges. Last but by no means least, they have given us an opportunity to become acquainted with many young Japanese scientists. We have been impressed by the quality of Japanese cancer research over and over again. Not that there was a need for this -I have learned the Japanese word Gann among the very first foreign words I started to learn when I entered the cancer research field more than 40 years ago. But it is wonderful to revisit an old friend who is getting younger, more vigorous and more productive with every year that goes by.
(Received January 1, It is a pleasure for me to thank your Imperial Highness on behalf of all those of us who have taken part in the exciting and stimulating Symposium on the Genetic Basis for Carcinogenesis: Tumor Suppressor Genes and Oncogenes. It is your Cancer Research Fund that we thank for making this Symposium possible.
I work for an organisation which has Imperial in its name from another Royal Family, with which I believe your family has close contacts, and which is also a cancer research fund based on the important principle of charitable support from those who have suffered from cancer themselves or who have seen it, as you have, in their close relatives and friends and so who have experienced its fearsome grip at first hand and who see, as you emphasised in your Opening Address to us, the urgency of doing research to achieve effective prevention and cure for this disease.
The support of your Fund for these symposia and other activities has, I know, had a far-reaching effect in Japan in stimulating interest and concern about cancer and of course in promoting effective advances in cancer research. But it has also had an important effect abroad through the many scientists who are brought to Japan for the symposia.
In my case, attending a previous symposium in 1981 was the opportunity for my first visit to Japan, as I know it is for several of the speakers at this Symposium. It is a marvellous opportunity not only to take part in an outstanding meeting with lively discussion, but also to meet Japanese colleagues and to hear more about the excellent research being done in your country. It is also a unique opportunity to establish fresh personal contacts with Japanese cancer research workers and to make friends, which is the basis for future collaboration between our various countries. Such international collaboration is essential, since cancer is an international problem that does not recognise any division between nations and their peoples.
Your Opening Address and Dr. Stanbridge's response emphasised the present enormous excitement in cancer research that comes particularly from our dramatically improved understanding of the carcinogenic process at the fundamental molecular genetic and biological levels.
This 20th Symposium has epitomised that excitement and has justified the Nobel Committee's decision to recognise the field by its Award to our friends and colleagues Harold Varmus, who has attended the Symposium, and Mike Bishop.
I believe we may be on the threshold of establishing a complete genetic phathology for most cancers, including especially some of the more refractory common cancers such as of the large bowel and stomach. This is a situation where the diagnosis will not predict prognosis but determine it, and positively through new, more specific and effective, treatments which will be developed from our improved fundamental understanding. This new understanding will, moreover, I feel sure be just as important for the primary objective of prevention as for treatment. It will surely help us to understand those factors in the diet which we know must be important, and which are, for example, reflected in the differences in incidence in various cancers between Japan and Western societies, namely a high incidence of stomach and a relatively low incidence of colon and breast cancer in Japan, but with a disturbing tendency to change toward the Western pattern.
We have here experienced your wonderful Japanese food. What features of these delicious dishes are responsible for those differences in cancer incidence? And how can we have the best of both worlds -the best Japanese and the best Western food -and yet low incidences of colon, breast and stomach cancer? The new biology must, we hope, answer these questions, and no doubt future symposia will discuss new diagnoses, new treatments, new screening procedures and new approaches to prevention based on the new understanding.
I must finish by again thanking you most warmly and sincerely for the magnificent hospitality during this Meeting -and of course at the same time acknowledge the tremendous effort put into the organisation and management of the Symposium by Doctors Terada, Sugimura, Watanabe and their young colleagues. We thank you personally for the beautiful flower arrangements, for your evocative poem, your stimulating Opening Address, and a magnificent Reception. But we thank you most of all for your support for the Princess Takamatsu Cancer Research Fund which has made this Symposium possible and hopefully many more like it in the years to come with ever more hope for improvements in the prevention and treatment of cancer. 
Closing Remarks for the 20th International Symposium of the Princess Takamatsu Cancer Research Fund
The presentations of the last three days have revolved around three major themes: positive growth regulators that can also act as dominant oncogenes, negative growth regulators that function as tumor suppressor genes, and the interaction of positive and negative growth regulators. Of these themes, the field of oncogenes is the most established one. Over the past twenty years it has gone through a period exponential growth, shaped by land mark discoveries that identified and defined retroviral oncogenes, traced their origins to the cell genome, and in a few fortuitous cases uncovered cellular genes of known functions that are progenitors of oncogenes. A few simple generalizations have emerged in this field. (4) It is a widely accepted idea that oncogenes acquire transforming activity through quantitative, rather than qualitative change, usually through some form of upregulation that results in the higher dosage or increased specific enzymatic activity, sometimes expressed in an inappropriate cell type or at an inappropriate time. The first exception to this rule was described at this meeting by Harold Varmus with the src host range mutants which show that a qualitative change in the src proteins affect transforming activity.
Negative growth regulators and tumor suppressor genes have come into prominence more recently, although the seminal work of Klein and Harris and of Knudsen antedates the flowering of the oncogene field. Negative regulators are more difficult to define operationally than are positive regulators. Tumor suppressor genes have been found by classical genetic studies, by cytogenetic techniques, RFLP analysis, and a few have been cloned and sequenced. Tumor suppression can noW been demonstrated not only with cell or microcell fusion, but also by introducing cloned and expressed single genes into transformed cells. We have learned of examples for this activity at this meeting. Specific biochemical functions of negative growth regulators still remain elusive, although DNA binding as with the RB-I protein or the zinc finger motifs as in the presumptive Wilms tumor gene provide clues. Further guidance may come from the interaction of tumor suppressor genes and DNA viral oncogenes. These interactions made up the third theme of this conference. They mark an astonishing convergence of two fields that used to be widely separated. Basic concepts and assumptions that were perceived as incompatible, namely, dominant tumor suppression on the one hand and dominant oncogenicity on the other have found coexistence in the interaction of tumor suppressor genes and oncogenes. Work on cancer genes had produced convergences before -the emancipation of retroviral oncogenes from virology thirteen years ago started a development that has brought viral oncology, experimental chemical carcinogenesis, and studies on human cancer together and has merged them into the larger field of molecular cell biology.
A basic underlying idea unites our work and the presentations at this meeting. It is the assumption that the root cause of cancer is genetic, that every cancer cell differs from its normal counter part by one or, more often, by several discrete genetic changes. These oncogenic changes may be virus induced or of cellular origin. The idea of genetic change as the basis for cancer, first expressed nearly 80 years ago by Boveri is clearly still a belief and it may not apply to all cancers (for a possible exception one need only think of the teratocarcinomas that can revert to non-malignant behavior and participate in normal embryonial development). But observations on the large majority of cancers strongly support a causal role of genetic changes -so this belief seems justified. I would like to reflect on the short term and long term consequences of this belief.
Short term, it is clear that a genetic analysis of cancer has been immensely successful. This fact was also evident at this meeting. Genetic analysis has identified causes, and is beginning to provide explanations. It has elevated cancer research to the status of an experimental, quantitative science. This success will serve as beacon for the near term development of the field -more oncogenes and especially more tumor suppressor genes will be identified, isolated, cloned, sequenced, and characterized. All of us who are involved in this work are good reductionists. We concentrate on one or a few genes and, quite naturally, these genes become the center of our personal universe. I have seen many summary slides, some at this meeting, depicting one gene in the middle, and a few other genes connected with arrows to it. The point is that the gene in the center varies with the speaker. This reductionist distortion is useful in an early exploratory stage of growth regulation but will lead only to very fragmentary understanding.
What about the longer term prospects? For my speculations here let me use an analogy. Let us consider the discovery of a mineral, an ore, a natural resource that is valuable and in demand. Unmapped reserves of this ore are believed to be plentiful but finite. In such a situation, prospectors will appear on the scene to locate new deposits and stake their claims, and mining companies will recover the ore. Research on cancer genes is presently in such an expansive state of prospecting and mining. What might happen when the deposits have all been depleted, when all the cancer genes have been found? At this point we will have, as Walter Bodmer remarked at this meeting, "the genetic blueprints of cancer." Such blueprints will be of great value in genetic counselling, in diagnosis, in prognostic evaluations. It is doubtful whether they will lead directly to effective therapy. For this we might require more epigenetic information on interactions between the proteins that are important in growth regulation. Unfortunately, our track record in uncovering and analyzing such interactions is not very good. One of the more frustrating periods in oncogene research has been the search for relevant targets of oncoproteins. We still do not know the targets of the Src protein, of the Myc protein, of the Fos protein, or the Jun protein, or any other oncoprotein, except of growth factors which target their specific receptors. At this conference, there were some encouraging signs that this situation may be changing. I have already mentioned Harold Varmus' host range mutants of src. They may lead us to important cellular targets of the Src oncoprotein. We have heard about the Fos, Jun, CREB-TGF,8 connections. The MyoD gene product interacts with the El2 and with the ID proteins. Then there are the complexes between Rb-l, p300, and p107 proteins, and adenovirus EIA protein, SV40 large T antigen, or the E6, E7 proteins of papilloma viruses. Some of these interactions already include multiple components, but they are usually treated as two component systems, isolated from the rest of the variables. Yet we readily acknowledge that we are dealing with integral components of larger regulatory chains and networks.
The main point I wish to make here is that when all cancer genes have been found as when all the deposits of an ore become exhausted, it will be time for new and more sophisticated approaches and technologies. At that juncture we will want to understand phenotype from information of genotype, and that means we will have to deal with complexity.
We do not know much about growth regulatory networks, but it seems safe to assume that they consist of multiple variables and components. These form compound entities whose characteristics are not found in their isolated parts. Biological regulation also usually includes feedback loops and has buffering capacity, yet is sensitive to small changes of the right kind and timing. We do not have the tools to analyze multi-variable systems of the complexity expected from growth regulation, but we can look around to see whether such tools are becoming available somewhere else.
There is indeed an emerging science of complexity popularly known as "chaos research.,,1-3) It is applied to such a wide variety of areas as prediction and model building in meteorology and economics, to analysis of heartbeat patterns or of population dynamics. It describes systems with multiple interdependent variables, applying non-linear equations and using such concepts as the "strange attractor," 4) and the newly developed geometry of fractals. '.6) Multiple feedback loops are dealt with and conditions of order and of chaos defined. I do not want to say that we should all turn to chaos research for methodological innovation and conceptual illumination. I just want to suggest that there are some tools there that at some time in the not-to-distant future we might want to try.
In summary, I believe the field of cancer genes to be well into a phase of prospecting and mining in which a reductionist approach is successful and appropriate. When all the mining is done, we will have to deal with complexity, and this may require new tools and perhaps fundamentally different thinking.
In closing, let me thank our hosts. The kindness and graceful energy of Her Imperial Highness Princess Takamatsu has been felt throughout this symposium. We were recipients of a magnificant hospitality that, in a unique way, blended elegance with warmth. On behalf of all the participants of this symposium, I wish to express our sincere thanks. Those of us who are veterans at these conferences also remember with fondness His Imperial Highness Prince Takamatsu. The reception for symposium paticipants three years ago was his last public appearance. Prince Takamatsu died of cancer not long thereafter. We honor in him a man of compassion, of kindness, of insight, of gentle humor, and of unfailing support for science.
